Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 4/20 | 0.56 |
| ▸ | CDK1 | P06493 | 4/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 2/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207326 | 1.00 | CCNB2 (0.56) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL2826129 | 1.00 | CCNB2 (0.56) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL2829682 | 0.89 | TGM2 (0.51) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL13207355 | 0.89 | TGM2 (0.51) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL2829685 | 0.89 | TGM2 (0.51) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL25684457 | 0.87 | TGM2 (0.47) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL25684746 | 0.87 | PDPK1 (0.47) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL2826461 | 0.86 | TGM2 (0.49) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL2826458 | 0.86 | TGM2 (0.49) | CCNB2CDK1CCNB1CCNB3HSP90AA1 | |
| SCHEMBL13207335 | 0.86 | TGM2 (0.49) | CCNB2CDK1CCNB1CCNB3HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781475-B2 | Oxindoles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-08-24 | — | — | US | claimed |
| US-20100197757-A1 | OXINDOLES AS KINASE INHIBITORS | BURGDORF LARS THORE | 2010-08-05 | — | — | US | claimed |
| EP-1891008-B1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2010-06-30 | — | — | EP | claimed |
| US-20090131506-A1 | Oxindoles as Kinase Inhibitors | MERCK PATENT GMBH (DE) | 2009-05-21 | — | — | US | claimed |
| EP-1891008-A1 | OXINDOLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006131186-A1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | WO | claimed |
| US-7781475-B2 | Oxindoles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20100197757-A1 | OXINDOLES AS KINASE INHIBITORS | BURGDORF LARS THORE | 2010-08-05 | — | — | US | disclosed |
| EP-1891008-B1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090131506-A1 | Oxindoles as Kinase Inhibitors | MERCK PATENT GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-1891008-A1 | OXINDOLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131186-A1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197757-A1 | OXINDOLES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K1 | CCNB2 741/4885CDK1 66/4885CCNB1 810/4885 |
| US-20090131506-A1 | Oxindoles as Kinase Inhibitors | MAP4K2, MAP3K20, MAP3K1 | CCNB2 741/4885CDK1 66/4885CCNB1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.